

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the September 1, 2017 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at <https://www.ab.bluecross.ca/dbl/publications.html>

Please refer to the September 1, 2017 Updates for complete listings of: products available by special authorization, products available by restricted benefit/special authorization, products available by step therapy/special authorization, drug products with changes to criteria for coverage, added products, new established interchangeable groupings, least cost alternative (LCA) price changes, products with a price change and discontinued listings.

Please note that the online *Interactive Drug Benefit List (iDBL)* at https://www.ab.bluecross.ca/dbl/idbl_main1.html is a near real-time application, and as such, contains the most up-to-date information.

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02244550) manufactured by Hospira Healthcare Corporation, Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02246597) manufactured by Fresenius Kabi Canada was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Hospira Healthcare Corporation has advised Alberta Blue Cross that the shortage of Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02244550) has been resolved.

As a result, Pamidronate Disodium 30 mg/10 ml Vial Injection (DIN 02246597) will no longer be considered a temporary benefit for the *ADBL* **after September 15, 2017.**

... continued from previous page

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Tobramycin 0.3% Ophthalmic Solution (DIN 02241755) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 18, 2017**.

TOBRAMYCIN

0.3 % OPHTHALMIC SOLUTION

00002241755	SANDOZ TOBRAMYCIN	SDZ	\$ 1.3620
00000513962	TOBEX	ALC	\$ 1.8580

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.701 2017/08

